We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+51.8%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$357M
AUM Growth
+$32.4M
(+10%)
Cap. Flow
-$34.5M
Cap. Flow
% of AUM
-9.67%
Top 10 Holdings %
Top 10 Hldgs %
41.79%
Holding
95
New
30
Increased
9
Reduced
31
Closed
21
Top Buys
| 1 |
C4 Therapeutics
CCCC
|
+$11.1M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$7.67M |
| 3 |
Perspective Therapeutics
CATX
|
+$6.91M |
| 4 |
Solid Biosciences
SLDB
|
+$6.83M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$6.54M |
Top Sells
| 1 |
MRSN
Mersana Therapeutics
MRSN
|
+$13.7M |
| 2 |
MacroGenics
MGNX
|
+$11.8M |
| 3 |
Medtronic
MDT
|
+$11.1M |
| 4 |
Sanofi
SNY
|
+$10.9M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
+$8M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
1
DELISTED
Merus
MRUS
| $25.5M | 7.15% |
566,287
-79,294
| -12% | -$3.22M |
|
|
2
Solid Biosciences
SLDB
$948M
| $17.6M | 4.95% |
1,325,065
+730,210
| +123% | +$6.83M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $17M | 4.78% |
483,972
-16,070
| -3% | -$539K |
|
4
Oric Pharmaceuticals
ORIC
$1.09B
| $15.3M | 4.29% |
1,113,007
-56,993
| -5% | -$677K |
|
|
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
| $13.3M | 3.73% |
118,752
-138,053
| -54% | -$13.7M |
|
6
Celldex Therapeutics
CLDX
$3B
| $12.6M | 3.52% |
299,316
+52,101
| +21% | +$2.14M |
|
|
RNAM
7
DELISTED
Avidity Biosciences
RNAM
| $12.5M | 3.5% |
+489,303
| New | +$7.67M |
|
8
Nuvalent
NUVL
$9.81B
| $11.8M | 3.32% |
157,750
-35,250
| -18% | -$2.81M |
|
|
9
C4 Therapeutics
CCCC
$421M
| $11.7M | 3.29% |
+1,435,931
| New | +$11.1M |
|
10
Praxis Precision Medicines
PRAX
$9.14B
| $11.6M | 3.26% |
190,556
-93,285
| -33% | -$4.18M |
|
|
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $11.5M | 3.22% |
3,596,476
-109,303
| -3% | -$364K |
|
|
AKRO
12
DELISTED
Akero Therapeutics
AKRO
| $10.1M | 2.83% |
399,949
+150,695
| +60% | +$3.62M |
|
|
13
Perspective Therapeutics
CATX
$348M
| $9.65M | 2.71% |
+810,811
| New | +$6.91M |
|
14
Rhythm Pharmaceuticals
RYTM
$7.54B
| $7.96M | 2.23% |
183,776
+9,528
| +5% | +$417K |
|
|
ALPN
15
DELISTED
Alpine Immune Sciences Inc
ALPN
| $7.89M | 2.21% |
199,020
-98,769
| -33% | -$2.91M |
|
16
UroGen Pharma
URGN
$1.91B
| $7.63M | 2.14% |
508,587
-16,817
| -3% | -$275K |
|
17
Gossamer Bio
GOSS
$68.5M
| $7.23M | 2.03% |
6,130,268
| – | – |
|
|
18
MacroGenics
MGNX
$273M
| $7.04M | 1.97% |
478,079
-780,562
| -62% | -$11.8M |
|
19
Cogent Biosciences
COGT
$6.58B
| $6.97M | 1.95% |
1,036,667
+69,919
| +7% | +$432K |
|
|
KALV
20
DELISTED
KalVista Pharmaceuticals
KALV
| $6.66M | 1.87% |
561,183
+449,449
| +402% | +$5.99M |
|
21
Kodiak Sciences
KOD
$2.71B
| $6.52M | 1.83% |
1,238,822
+238,822
| +24% | +$1.17M |
|
22
Veracyte
VCYT
$4.52B
| $6.22M | 1.74% |
280,773
+33,050
| +13% | +$806K |
|
23
Crinetics Pharmaceuticals
CRNX
$8.86B
| $5.98M | 1.68% |
+127,835
| New | +$5M |
|
24
Olema Pharmaceuticals
OLMA
$1.04B
| $5.83M | 1.64% |
515,317
-58,513
| -10% | -$755K |
|
|
BBOT
25
BridgeBio Oncology
BBOT
$707M
| $5.2M | 1.46% |
+500,000
| New | +$5.18M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA